Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 85,947 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Weight reduction training, PPG training, discrete BG feedback, continuous BG feedback; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 80 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Prostate Cancer, Prostate Cancer Metastatic
Interventions: Counseling Tool, Questionnaires; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Childhood Cancer
Interventions: Mila Blooms; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 12 Years to 19 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Renal Insufficiency
Interventions: QAW039, QAW39A, QAW39A2107; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Transient Insomnia
Interventions: SM-1, D+Z, D+L, Placebo; Drug
Lead sponsor: Sequential Medicine Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Asthma in Children
Interventions: Clinical decision support + education (CDS+) and population health management (PHM), Control; Behavioral · Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years to 18 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Participants
Interventions: AZD5004; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Genotype 1 Chronic Hepatitis C
Interventions: GI-5005, Pegylated Interferon and Ribavirin; Drug
Lead sponsor: GlobeImmune; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 25
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 21 more

Conditions: Colorectal Carcinoma
Interventions: Media Intervention, Best Practice, Questionnaire Administration; Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 45 Years to 75 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer
Interventions: Lapatinib, Paclitaxel, 5-Fluorouracil (5-FU), Epirubicin, Cyclophosphamide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hormone-Sensitive Breast Cancer, Breast Cancer
Interventions: Letrozole, Bevacizumab; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Neoplasms, Breast
Interventions: capecitabine, topotecan, lapatinib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 13
States / cities: Washington D.C., District of Columbia • Indianapolis, Indiana • Sioux City, Iowa + 10 more

Conditions: Sickle Cell Disease
Interventions: WEB-MAP Educational Control Group, WEB-MAP CBT; Behavioral
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 11 Years to 18 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Allogeneic Myeloma Vaccine, Prevnar-13; Drug · Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COVID-19
Interventions: AZD7442, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 910 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 24
States / cities: Jasper, Alabama • Tucson, Arizona • Long Beach, California + 17 more

Conditions: Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Oligoastrocytoma
Interventions: Bevacizumab, MLN-518 (Tandutinib), Quality-of-life assessment; Biological · Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: LowT, Resistance Training, Placebo, HighT; Drug · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 60 Years and older · Male only
Enrollment: 167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Advanced Breast Cancer
Interventions: Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib, Fulvestrant, Letrozole, Anastrozole, Exemestane; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 788 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 57
States / cities: Gilbert, Arizona • Fountain Valley, California • Glendale, California + 49 more

Conditions: Progressive Myoclonus Epilepsy Type 1, EPM1, CSTB-related Disease, Myoclonus Epilepsies, Progressive, Unverricht-Lundborg Disease, Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature, PME, Progressive Myoclonus-Epilepsies
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Total Hip Arthroplasty
Interventions: Real-time Instrumentation, Standard Total Hip Arthroplasty; Device · Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Head and Neck Cancer
Interventions: cisplatin, cytochlor, tetrahydrouridine, radiation therapy; Drug · Radiation
Lead sponsor: University of Miami; Other
Eligibility: 21 Years to 120 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pancreatic Neoplasms, Bile Duct Neoplasms
Interventions: Oxaliplatin, Capecitabine, Sorafenib; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pediatric Multiple Sclerosis
Interventions: ABMT mobile application; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 12 Years to 24 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Traumatic Brain Injury
Interventions: Blood/saliva sampling; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Treating Type 2 Diabetes by Reducing Postprandial Glucose Elevations: A Paradigm Shift in Lifestyle Modification

Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer

Mila Blooms Intervention Study

Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects

SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.

SMART Implementation-Effectiveness Trial 2

A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection

A Video Intervention to Decrease Patient Fear of Colonoscopy After a Positive Fecal Immunochemical Test

Phase II Neoadjuvant in Inflammatory Breast Cancer

Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer

Brain Metastases In ErbB2-Positive Breast Cancer

Web-MAP Intervention for Youth With Sickle Cell Disease

Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

TEAM: Testosterone Supplementation and Exercise in Elderly Men

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Registry and Natural History Study for Progressive Myoclonus Epilepsy Type 1 (EPM1)

Real-Time Instrument for Acetabular Shell Positioning

Cytochlor and Tetrahydrouridine as Radiosensitizers and Cisplatin Combined With Radiation Therapy in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (Mouth) or Oropharynx (Throat)

CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma

Mobile Attentional Bias Modification Training in Pediatric MS

A Pilot Study to Identify Biomarkers Associated With Chronic Traumatic Brain Injury